Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Announces Plans to Release Benchtop UST-Based BaroShear Instrument in Q3 2020

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced its plans to release a benchtop, R&D scale, Ultra Shear Technology(TM) (“UST”)-based BaroShear instrument to the market in the third quarter of 2020. Per the update, Pressure BioSciences believes this new instrument will address a significant un-met need in product formulation and development laboratories throughout cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. “We are very excited about the planned release later this year of the third instrument in the BaroShear product family. The aggressive marketing campaign we have underway for the pre-sale of our BaroShear K45 system and for the 2021 release of our industrial-scale BaroShear Max instrument has been well received by manufacturing laboratories,” Director of PBI’s UST Program, Kenneth F. Micciche, said in the news release. “However, it has become apparent that product research and development labs prefer a smaller, bench-top, lower price-point, minimal throughput UST-based instrument. The BaroShear Mini clearly answers that need and will do so without cannibalizing sales to larger manufacturing facilities.  We believe this new instrument will add significantly to PBI’s revenue in 2020.”

To view the full press release, visit

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO. Bookmark the permalink.

Comments are closed.